Conference Chairman Richard DiCicco (Harvest Moon Pharmaceuticals) Provides Exclusive Interview Prior To Biosimilars North America 2016

The Biosimilars North America meeting will take place on November 16-17, 2016, New Jersey, USA.

It's without doubts that the biosimilar market presents lucrative opportunities for pharmaceutical and biotech companies. Over the last 12 months, market participants have witnessed revolutionary steps in the U.S. to facilitate commercialization.

The 3rd Annual Biosimilars North America conference will provide timely discussion with case studies on how to commercialize biosimilars, latest market developments, and regulatory updates to ensure you stay at the forefront of this evolving market.

In the run up to the event, the SMi Group caught up with the conference chairman: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc., for an exclusive interview, revealing his thoughts on the biosimilar market in the U.S., approval process, regulatory framework, and much more.

In the interview Richard DiCicco said about the approval process in the U.S.:

"We have three approved biosimilar mAb products in the US in 2016 totalling four biosimilars... FDA has optimized and streamlined the approval process...Once the sponsors are able to develop robust presentations with their data statistically presented by the FDA statisticians to the Advisory Committees, approval comes quickly and unanimously. Once the insurance coverage gaps are filled, the initial biosimilar entrance will behave as branded biologics but eventually the market will become commoditized as a deeply discounted generic market from what we have seen in Europe."

To download the full interview please visit: https://www.smi-online.co.uk/pharmaceuticals/northamerica/biosimilars-north-america#tab_downloads

Unrivalled speaker line up in 2016 will include:

• Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals
• Gustavo Grampp, Ph.D., Director R&D Policy - Biosimilars, Amgen Inc.
• Andrew Simpson, Scientific Director, Orygen Biotechnologia S/A
• Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US
• Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfizer Inc., and many more.

Conference will also feature two interactive pre-conference workshops:

A: Leveraging Successful Patient Recruitment & Retention Strategies in Biosimilars Research
Led by Shazia Ahmad, Director, Patient & Physician Services, UBC - An Express Scripts Company

B: Biosimilars: Considerations for Optimizing Access and Price
Led by: Mkaya Mwamburi, Vice President, HEOR/Evidence Generation, MKTX Market Access Solutions, LLC

2016 event is sponsored by: Abzena, Schwegman, Lundberg & Woessner, P.A. and Wyatt Health Management

For more information, visit www.biosimilars-northamerica.com/bdev

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business conferences, workshops, masterclasses, and online communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance, and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share, and Network. For more information, visit http://www.smi-online.co.uk